CasImg
盐酸美加明
产品纠错
CAS号:826-39-1 | 英文名称:UNII:4956DJR58O
分子式 C11H22ClN
分子量 204
EINECS号 212-555-8
MDL MFCD00151462
Smiles
InChIKey
乙二醇化学百科
基本信息
中文名称 盐酸美加明
英文名称 Mecamylamine hydrochloride
CAS号 826-39-1
分子式 C11H22ClN
分子量 203.75
EINECS号 212-555-8
物化性质
熔点 >240°C (dec.)
溶解度 乙醇:122 mg/mL
形态 固体
酸度系数(pKa) pKa 11.2(H2O,t undefined,I=0.1) (Uncertain)
颜色 白色至米白色
稳定性 吸湿性
安全信息
危险品标志 Xn
危险类别码 22-36/37/38
安全说明 36/37/39
危险品运输编号 UN 2811 6.1/PG 3
WGK Germany 3
RTECS号 RB6900000
海关编码 2921300000
危险等级 6.1
生产及用途
Mecamylamine hydrochloride 是一种具有口服活性,非选择性,非竞争性 nAChR 拮抗剂,具有抗神经疾病作用。Mecamylamine hydrochloride 是一种神经节阻滞剂,有潜力用于高血压研究。Mecamylamine hydrochloride 可以很容易地穿过血脑屏障。

nAChR

Mecamylamine blocks muscle nAChRs in a use- and voltagedependent manner. Mecamylamine blocks the nicotinic currents via trapping mechanism. The main feature of this block is the phenomenon of block relief, which might be revealed by combined action of depolarization and activation of nAChRs. The experimental study of the Mecamylamine action on muscle nAChRs revealed that: (1) Mecamylamine (1-20 μM) reduces evoked end-plate currents (EPC) amplitude with Hill’s constant equal to 1.2 and IC 50 = 7.8 μM at holding potential –70 mV; (2) the calculated depth of its interaction with the muscle nAChR channel is almost half of the one of neuronal nAChRs (0.37 compare to 0.72 for neuronal nAChRs); (3) simultaneous membrane depolarization and repetitive activation of postsynaptic nAChRs by motor nerve stimulation produced rapid block relief dependent on the degree of depolarization, number of conditioning signals and Mecamylamine concentration, and only slightly depended on the rate of stimulation.

Mecamylamine (0.5-1 mg/kg; Intraperitoneal injection; C57BL/6J mice) has antidepressant-like effects in both the TST and FST and these effects are dependent on bothβ2 andα7 subunits.

Animal Model: C57BL/6J mice (3-4 months) forced swim test (FST) and tail suspension test (TST)
Dosage: 0.5 mg/kg, 0.75 mg/kg, 1 mg/kg
Administration: Intraperitoneal injection
Result: Significantly decreased immobility time in the TST at the 1.0-mg/kg dose but did not alter baseline locomotor activity. Also significantly decreased time immobile in the FST.
产品供应商
826-39-1
上海阿拉丁生化科技股份有限公司
2023-10-02

首页 |  CAS目录 |  产品目录 |  企业会员 |  关于我们 |  法律声明 |  注册协议

Copyright © 冀ICP备2024096099号